Search results
Showing 2901 to 2950 of 3803 results for treatment
In development Reference number: GID-TA11663 Expected publication date: TBC
familial hypocalciuric hypercalcaemia (FHH) because it needs no operative treatment. Evidence showed that the 3 tests recommended are...
identified, therefore decisions on treatment can be made earlier in the diagnosis pathway saving on future treatment costs....
core set of relevant health outcome measures should be used for trials of treatments for ME/CFS and managing symptoms of ME/CFS? Any...
NICE has developed a medtech innovation briefing (MIB) on Aquablation robotic therapy for lower urinary tract symptoms caused by benign prostatic hyperplasia .
serology is likely to remain positive for some time following successful treatment of infection in most patients. However, little is...
This guidance has been withdrawn because Novartis has discontinued ofatumumab (Arzerra). Ofatumumab will continue to be available for people who need it. Contact Clinigen at managedacess@clinigengroup.com or 01932 842100 for details.
We have moved interventional procedures guidance 545 to become HealthTech guidance 399. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
Exploratory work regarding the use of bevacizumab in the treatment of eye conditions [ID422]
Discontinued Reference number: GID-TA11205
Comparator, Outcome) P: people hospitalised because of COVID-19 I: treatment with different doses of casirivimab and imdevimab C: •...
NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .
This guideline covers supporting the social and emotional wellbeing of vulnerable children under 5 through home visiting, childcare and early education. It aims to optimise care for young children who need extra support because they have or are at risk of social or emotional problems.
Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer (TA107)
This guideline has been updated and replaced by NICE guideline NG101.
Discontinued Reference number: GID-MT130
directly compare eltrombopag with non-thrombopoietin receptor agonist treatments routinely used in UK clinical practice. Any explanatory...
deliver the injection. Patient adherence to treatment may be improved with anoral rather than injectable treatment.A large...
We have moved interventional procedures guidance 617 to become HealthTech guidance 474. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
NICE has developed a medtech innovation briefing (MIB) on Helge for detecting haemolysis .
New take at home drug recommended for people with chronic lymphocytic leukaemia
Our latest draft guidance recommends pirtobrutinib, a new take at home tablet, that could give patients greater choice and reduce the need for frequent hospital visits.
Neuropad for detecting preclinical diabetic peripheral neuropathy (HTG486)
Evidence-based recommendations on Neuropad for detecting preclinical diabetic peripheral neuropathy.
The principles that guide the development of NICE guidance and standards.
procedure, whether or not other adjunctive treatments are used. Research should document adjunctive treatments and details...
NICE has developed a medtech innovation briefing (MIB) on SuperNO2VA for the relief of upper airway obstruction in people with obstructive sleep apnoea .
no evidence base for clinicians to make decisions with regards to the treatment options available. Antimuscarinics are used first-line...
Medicines management for people receiving social care in the community (QS171)
This quality standard covers assessing if people need help with their medicines and deciding what medicines support is needed to enable people to manage their medicines. It also includes communication between health and social care staff, to ensure people have the medicines support they need. It describes high-quality care in priority areas for improvement.
View quality statements for QS171Show all sections
This quality standard covers the additional antenatal care for women who are pregnant with twins or triplets that is offered alongside routine antenatal care. It describes high-quality care in priority areas for improvement.
View quality statements for QS46Show all sections
Sections for QS46
- Quality statements
- Quality statement 1: Determining chorionicity and amnionicity
- Quality statement 2: Labelling the fetuses
- Quality statement 3: Composition of the multidisciplinary core team
- Quality statement 4: Care planning
- Quality statement 5: Monitoring for fetal complications
- Quality statement 6: Involving a consultant from a tertiary level fetal medicine centre
- Quality statement 7: Advice and preparation for preterm birth
The clinical and cost effectiveness of proton pump inhibitors for the treatment of dyspepsia (TA7)
This guidance has been replaced by NICE guideline CG17. [Replaced by NICE guideline CG184]
We have moved interventional procedures guidance 199 to become HealthTech guidance 127. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 544 to become HealthTech guidance 398. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
experiencing wound dehiscence following surgery, which may reduce the costs of treatment. However, the committee acknowledged that there...
Evidence-based recommendations on VA ECMO for extracorporeal cardiopulmonary resuscitation (ECPR) in adults with refractory cardiac arrest. This involves using an artificial lung to oxygenate the blood outside the body.
Autism spectrum disorder in adults: diagnosis and management (CG142)
This guideline covers diagnosing and managing suspected or confirmed autism spectrum disorder in people aged 18 and over. It aims to improve access and engagement with interventions and services, and the experience of care, for people with autism.
NICE has developed a medtech innovation briefing (MIB) on TopClosure Tension Relief System for wound closure .
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.
there is no evidence exploring the psychological impact of the different treatments for ectopic pregnancy. However, the emotional impact...
Fetal cystoscopy for the diagnosis and treatment of lower urinary outflow tract obstruction (IPG205)
We have moved interventional procedures guidance 205 to become HealthTech guidance 131. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
We have moved interventional procedures guidance 693 to become HealthTech guidance 577. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
description of patient selection, and details of adjunctive medical and surgical treatments. Outcomes should include GORD symptoms,...
potentially improve survival if people recover enough to have more effective cancer treatments. The outcomes of interest are:-...
This document is one of a series describing the processes and methods that NICE uses to carry out technology appraisals. It focuses on the technology appraisal processes
rivaroxaban or dabigatran etexilate, as there are no antidotes or established treatments to stop active bleeding for these agents. Any...
Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia (TA142)
This guidance has been replaced by NICE technology appraisal guidance 323.
A step-by-step timeline of the process we used to develop single technology appraisals (STA).
Bed frames for adults in acute medical or surgical hospital wards: late-stage assessment (HTG759)
Late stage assessment (LSA) guidance on bed frames for adults in acute medical or surgical hospital wards.
Omalizumab for the treatment of severe persistent allergic asthma in children aged 6–11 (TA201)
This guidance has been updated and replaced by NICE technology appraisal guidance 278.
common uterine pathologies in women presenting with HMB. Pharmacological treatments appear to be less effective in the presence of these...
the condition and ways of managing it that support surgical and medical treatment. However, no high-quality research was identified on...
Furthermore, pain management programmes have not been compared with other treatments available for endometriosis. Pain management...
We have moved interventional procedures guidance 772 to become HealthTech guidance 693. This is to better reflect the NICE HealthTech programme which combines the former NICE Diagnostics Assessment programme, Interventional Procedures programme and Medical Technologies Evaluation programme and to help you find relevant content more quickly. The guidance itself has not changed.
This guideline has been updated and replaced by NICE guideline NG101.